Parkinson’s Disease – Current Treatment – Current Treatment: Physician Insights – Parkinson’s Disease (US)
The mature Parkinson’s disease treatment market continues to evolve as newly launched pump therapies (i.e., AbbVie’s Vyalev, Supernus’s Onapgo), extended-release levodopa formulations (i.e., Amneal’s Rytary and Crexont), and branded adjunctive therapies (e.g., Amneal’s Ongentys, Kyowa Kirin’s Nourianz, Supernus’s Gocovri) establish niches in the treatment algorithm. These newer brands are designed to optimize and prolong levodopa’s benefits, reduce the severity of levodopa-induced dyskinesia, and reduce the frequency and impact of motor response complications. Understanding neurologists’ prescribing decisions in PD and the underlying drivers is crucial for developers in this competitive market and those striving to enter it. With generic alternatives available in all PD drug classes, it will be critical for new brands to demonstrate clear clinical differentiation to gain uptake.
Questions answered
- What comorbidities are most common in PD patients, and which are most difficult to manage? Which clinical attributes define early, intermediate, and advanced PD?
- What is the patient share for key brands and how do neurologists expect their prescribing to change in the coming year? What are the key drivers and constrainers of their use?
- What percentage of Parkinson’s patients develop motor fluctuations or levodopa-induced dyskinesias? What strategies do neurologists use to manage these issues?
- What percentage of PD patients receive treatment for nonmotor symptoms (e.g., orthostatic hypotension, psychosis, dementia)?
- How are neurologists using biomarker testing (e.g., alphasynuclein, LRRK2, GBA, DAT)?
Product description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
Markets covered: United States
Key companies: AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Lundbeck, Supernus
Key drugs: Crexont, Vyalev, Onapgo, Duopa, Gocovri, Inbrija, Neupro, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays
Primary research: Survey of 100 U.S. neurologists
